Canine Norovirus

Overview and Taxonomy of Canine Norovirus

Canine norovirus (CNV) represents a recently recognized, yet increasingly significant, enteric pathogen within the Caliciviridae family, genus Norovirus. First identified in 2007 from a pup with enteritis in Italy [8, 17], CNV has since been detected in canine populations across Europe, Asia, the Americas, and the Middle East, establishing its global distribution [1, 3, 4, 6, 14, 16]. Noroviruses are small, non-enveloped, positive-sense single-stranded RNA viruses, and their genetic architecture, characterized by a tripartite genome encoding non-structural proteins (including the RNA-dependent RNA polymerase, RdRp), a major capsid protein (VP1), and a minor structural protein (VP2), underpins both their remarkable diversity and their pathogenic potential [10, 20]. Within the broader context of norovirus biology, which is dominated by the immense human disease burden caused by genogroups GI and GII, CNV occupies a distinctive ecological and evolutionary niche. The World Health Organization (WHO) has identified norovirus as a priority for vaccine development due to its global impact on human health, and the emergence of noroviruses in companion animals, particularly dogs, introduces critical questions regarding cross-species transmission, reservoir dynamics, and the implications for both veterinary and public health [19, 22]. The United States Centers for Disease Control and Prevention (CDC) and the World Organisation for Animal Health (WOAH) also recognize the importance of surveillance for emerging zoonotic pathogens, making the study of CNV taxonomy and epidemiology a matter of dual concern [13].

Taxonomically, noroviruses are classified into genogroups and further subdivided into genotypes based on the amino acid diversity of the complete VP1 capsid protein, with a parallel classification of P-types based on the nucleotide diversity of the RdRp region in ORF1 [21]. The most recent, widely accepted classification scheme, as established by the international norovirus classification-working group, expanded the number of genogroups to ten (GI–GX) and the number of genotypes to 49 [21]. CNV strains are predominantly assigned to genogroup VI (GVI), with two well-established genotypes: GVI.1 and GVI.2 [1, 2, 21]. However, canine noroviruses have also been identified in genogroup IV (GIV) and, more recently, in genogroup VII (GVII), underscoring the profound genetic heterogeneity of noroviruses circulating in carnivores [3, 9, 16, 18]. The prototype GVI.1 strain, Bari/91/2007/ITA, and the GVI.2 strain, C33/Viseu/2007/PRT, were among the first fully characterized from dogs [2, 8]. Subsequent phylogenetic analyses have revealed a far more complex picture. For instance, strain 5010/2009/ITA, identified in Italy, displayed only 66.6–67.6% nucleotide and 75.5–81.6% amino acid identities in the VP1 region to GVI.1 and GVI.2 strains, leading to its proposal as the prototype of a third GVI genotype, GVI.3 [2]. This discovery provided crucial evidence for the ongoing diversification of noroviruses within the canine host and challenged the then-prevailing view of limited genetic variability in animal noroviruses [2].

The genetic landscape of CNV is further complicated by the existence of strains clustering within GIV. While GIV noroviruses include human strains (GIV.1) and feline/canine strains (GIV.2), phylogenetic analyses consistently demonstrate that animal GIV.2 sequences form a distinct cluster separate from human GIV.1 sequences, suggesting host-specific adaptation [18, 21]. In a seminal study from South Korea, CNV strains detected in 3.1% of fecal samples were phylogenetically classified within the GIV genogroup, clustering with previously reported GIV.2 canine/feline strains [3]. Similarly, strains from Italy and Japan have been characterized as GIV.2, and these viruses have been detected in both dogs and cats, indicating a potential for interspecies transmission within domestic carnivores [11, 12, 15]. The identification of a novel norovirus in foxes in China, clustering with canine GVII strains and sharing 86.0–86.2% amino acid identity in VP1, further expands the known host range and genetic diversity of carnivore noroviruses [9]. This finding, coupled with the detection of GVII CNV in Brazil, suggests that GVII may represent a more widespread and genetically diverse group than initially appreciated [9, 16]. The genomic analysis of GVI and GIV strains has revealed the presence of chimeric viruses (e.g., GVI/GIV recombinants) exclusively in animal strains, indicating unique evolutionary pressures and recombination-driven diversification in canine and feline hosts that are not observed in human noroviruses [18].

The primary molecular mechanism driving norovirus diversity is mutation, attributable to the error-prone nature of the viral RdRp, which lacks proofreading capability. This results in a high mutation rate, estimated at approximately 10⁻³ to 10⁻⁵ substitutions per site per year, facilitating rapid genetic drift and the emergence of new variants [23]. For CNV, this is evident in the phylogenetic clustering of GVI.2 strains from different geographic regions. For example, complete genome sequencing of the Chinese GVI.2 strain Dog/M9/18/CH revealed 95.9% nucleotide identity to the sole previously available nearly complete GVI.2 genome, demonstrating significant divergence even within a single genotype [1]. Phylogenetic analyses of RdRp fragments from 21 CNV-positive samples in China showed that 18 strains clustered in GVI.2, two in GVI.1, and one in GIV.2, illustrating the co-circulation of multiple genogroups and genotypes within a single geographic region and timeframe [1]. A second, equally potent engine of norovirus evolution is recombination, which occurs primarily at the ORF1-ORF2 junction. This process can generate chimeric viruses with novel antigenic and biological properties. Recombination is a well-documented phenomenon in CNV, with evidence of GVI/GIV inter-genogroup recombination, as well as recombination between GVI strains [12, 18]. A notable example is the feline norovirus strain TE/77-13/ITA, which was genetically closest to canine GVI.2 strains in the VP1 region but carried a different ORF1 sequence, suggesting a recombination event at the ORF1-ORF2 junction [12]. This highlights the unrestricted flow of genetic material between canine and feline noroviruses, a feature that can accelerate diversification and potentially facilitate host-switching events. The epidemiological patterns observed in canine populations mirror some aspects of human norovirus infection. For instance, an outbreak in a Portuguese kennel demonstrated an incubation period of less than 48 hours, rapid dissemination among all dogs within two days, self-limiting diarrheal disease, and viral shedding lasting less than seven days, features strikingly similar to human norovirus outbreaks [5]. Seasonal peaks in CNV shedding during winter months have also been observed, a well-established epidemiological feature of human norovirus infections [6]. These parallels suggest that similar ecological and immunological drivers govern norovirus transmission across host species.

In conclusion, the taxonomy of canine norovirus is dynamic and rapidly expanding, moving beyond the initial classification of a single genogroup (GVI) with two genotypes. Current evidence establishes CNV as a genetically diverse group of viruses spanning at least three genogroups (GIV, GVI, GVII) and multiple genotypes, with ongoing evolution through mutation and recombination. The close phylogenetic relationships between canine, feline, and fox noroviruses, combined with the detection of CNV-specific antibodies in human populations, particularly in veterinarians, underscores the critical need for continued surveillance and genomic characterization to delineate the full spectrum of CNV diversity and assess its zoonotic potential [7, 13, 17].

Molecular Pathogenesis and Genetic Diversity of Canine Norovirus

Genomic Architecture and Phylogenetic Classification

Canine norovirus (CNV) is a non-enveloped, positive-sense single-stranded RNA virus belonging to the family Caliciviridae, genus Norovirus. The viral genome is approximately 7.6 to 8.0 kilobases in length and is organized into three open reading frames (ORFs). ORF1 encodes a large polyprotein that is post-translationally cleaved into seven non-structural proteins, including the RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. ORF2 encodes the major capsid protein VP1, which is the primary determinant of antigenicity, host receptor binding, and phylogenetic classification. ORF3 encodes a minor structural protein VP2, which plays a role in capsid stability and genome encapsidation. The complete genome of the GVI.2 strain Dog/M9/18/CH, sequenced from mainland China, is 7,905 nucleotides in length, sharing 95.9% nucleotide identity with the only previously available nearly full-length GVI.2 genome [1]. This genomic conservation, particularly within genogroups, underscores the evolutionary constraints imposed by the need to maintain structural and functional integrity.

Phylogenetically, noroviruses are classified into at least ten genogroups (GI through GX) and 49 genotypes based on the complete VP1 amino acid sequence, with additional P-types defined by the RdRp nucleotide sequence [21]. Canine noroviruses are predominantly classified within genogroups GIV, GVI, and GVII. Within GVI, two distinct genotypes have been well-characterized: GVI.1 and GVI.2. A third putative GVI genotype, represented by the Italian strain 5010/2009/ITA, has been proposed based on its VP1 sequence displaying only 66.6–67.6% nucleotide and 75.5–81.6% amino acid identity to established GVI.1 and GVI.2 strains, as well as feline GVI strains [2]. This finding provides compelling evidence for the ongoing genetic diversification of noroviruses within carnivore hosts. Furthermore, a novel norovirus identified in foxes in China was classified within GVII, sharing 86.0–86.2% and 91.9% amino acid identity in VP1 and RdRp, respectively, with canine GVII strains, suggesting a broader host range and cross-species transmission potential within the Canidae family [9]. The classification system, as updated by the international norovirus classification-working group, now recognizes two genotypes for GIV (GIV.1 in humans, GIV.2 in canines and felines) and two for GVI (GVI.1 and GVI.2), with GVII currently containing a single genotype [21]. This genetic architecture provides the foundation for understanding the molecular mechanisms of pathogenesis and the evolutionary dynamics that drive CNV emergence.

Molecular Mechanisms of Pathogenesis and Host Cell Tropism

The pathogenesis of CNV is initiated by viral attachment to host cellular receptors, a critical step that determines host range and tissue tropism. Human noroviruses (HuNoVs) are known to bind to histo-blood group antigens (HBGAs), a family of complex carbohydrates expressed on the surface of intestinal epithelial cells and in mucosal secretions. The susceptibility to HuNoV infection is largely determined by the host’s genetic makeup, specifically polymorphisms in the FUT2 (secretor) and FUT3 (Lewis) genes, which govern HBGA expression [38]. For CNV, seminal work using virus-like particles (VLPs) demonstrated that both GIV and GVI CNV strains interact with HBGAs, specifically recognizing α1,2-fucose-containing H and A antigens [31]. This binding specificity was confirmed through enzyme-linked immunosorbent assays (ELISAs) using canine saliva and tissue samples, as well as immunohistochemistry and blockade studies. The recognition of HBGAs by CNV is a striking parallel to HuNoV, raising important questions about the evolutionary origins of norovirus receptor usage and the potential for zoonotic transmission. The presence of α1,2-fucose residues on canine gastrointestinal tissues has been confirmed, and phenotyping studies have demonstrated that these antigens are expressed in a population of dogs, providing a molecular basis for host susceptibility [31].

Following attachment, the virus must enter the host cell, a process that remains incompletely understood for CNV. However, studies on HuNoV using human intestinal enteroids (HIEs) have revealed critical insights. For instance, bile acids, particularly glycochenodeoxycholic acid (GCDCA), are essential for the replication of certain HuNoV genotypes (e.g., GII.3) by promoting endosomal uptake, endosomal acidification, and the activity of acid sphingomyelinase, leading to increased ceramide levels on the apical membrane [35]. Given the phylogenetic relatedness and shared HBGA binding, it is plausible that similar co-factors may influence CNV entry and replication in canine intestinal cells. Once inside the cell, the virus must subvert host antiviral defenses. HuNoV replication in intestinal epithelial cells (IECs) induces an interferon (IFN) response, and the virus is sensitive to IFN-mediated restriction [40]. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, as well as RNA polymerase II-mediated transcriptional responses, are key components of this restriction [40]. Noroviruses have evolved strategies to evade these responses; for example, murine norovirus (MNV) infection results in a redistribution of the RNA-binding protein G3BP1 to viral replication complexes, thereby avoiding the formation of canonical stress granules that would otherwise halt protein synthesis and limit viral propagation [42]. Whether CNV employs similar mechanisms to manipulate the host stress response and evade innate immunity remains an active area of investigation.

The cellular tropism of noroviruses has been a subject of intense study. In humans, HuNoV has been shown to infect chromogranin A-positive enteroendocrine cells (EECs) in the small intestine, as well as other epithelial cells [37]. In mice, MNV specifically targets tuft cells, a rare type of intestinal epithelial cell that expresses the CD300lf receptor [43]. Tuft cell proliferation is driven by type 2 cytokines (IL-4 and IL-25), which are induced by the host immune response and the presence of commensal microbiota. This creates a feedback loop where the immune system inadvertently promotes viral infection by expanding the pool of susceptible target cells [43]. Furthermore, commensal bacteria have been shown to regulate the regionalization of MNV infection along the intestinal tract, inhibiting infection in the proximal small intestine via bile acid-mediated priming of type III interferon, while simultaneously stimulating infection in distal regions [39]. These complex interactions between the virus, host immunity, and the microbiome are likely to be critical determinants of CNV pathogenesis and clinical outcome, although direct evidence in dogs is currently lacking.

Genetic Diversity and Evolutionary Dynamics

The genetic diversity of CNV is a hallmark of its biology, driven by two primary mechanisms: the accumulation of point mutations (genetic drift) and recombination. The RdRp of noroviruses lacks proofreading activity, resulting in a high mutation rate that fuels the emergence of new variants. This is particularly evident in the VP1 capsid gene, where mutations can alter antigenicity and receptor binding properties, allowing the virus to escape pre-existing herd immunity. In humans, GII.4 noroviruses are notorious for their epochal evolution, where new pandemic variants emerge every 2–4 years due to the accumulation of amino acid substitutions in antigenic sites of VP1 [23]. For CNV, phylogenetic analyses of partial RdRp and VP1 sequences from global isolates have revealed a substantial degree of genetic heterogeneity. Studies from China have shown that among 21 CNV-positive samples, 18 strains clustered in GVI.2, two in GVI.1, and one in GIV.2 [1]. Similarly, a study in South Korea identified CNV strains that phylogenetically clustered with GIV genogroup [3]. In Portugal, a longitudinal study from 2007–2011 found that all CNV sequences contained the GLPSG amino acid motif characteristic of the NoV RdRp and shared 98–100% nucleotide identity, suggesting the circulation of a dominant strain within that geographic region during that period [6]. However, the identification of a novel GVI genotype in Italy (strain 5010/2009/ITA) [2] and the detection of GVII strains in Brazil [16] and foxes in China [9] indicate that the true diversity of CNV is far greater than initially appreciated.

Recombination is a powerful evolutionary force in noroviruses, occurring most frequently at the ORF1-ORF2 junction. This process generates chimeric viruses with novel combinations of non-structural (polymerase) and structural (capsid) genes, which can have altered fitness, transmissibility, and antigenicity. In human noroviruses, recombinant strains such as GII.2[P16] and GII.4[P16] have become globally dominant, demonstrating the epidemiological significance of this mechanism [33, 36]. Evidence for recombination in CNV has been documented. A novel feline norovirus strain, TE/77-13/ITA, was found to have a GVI.2 capsid but a polymerase region that was genetically closest to GIV.2 strains, with the crossover site mapped to the ORF1-ORF2 junction [12]. This finding suggests that interspecies transmission and recombination between canine and feline noroviruses can occur, potentially accelerating genetic diversification. Furthermore, genomic analyses of GIV and GVI noroviruses have revealed the existence of GVI/GIV chimeric viruses, although such recombinants appear to be restricted to animal strains, indicating that host-specific factors may limit the viability of certain recombination events [18]. The emergence of these chimeric viruses highlights the dynamic nature of the norovirus genome and the potential for rapid adaptation to new hosts or environmental niches.

Global Molecular Epidemiology and Zoonotic Implications

The molecular epidemiology of CNV has been elucidated through a growing number of surveillance studies across multiple continents. The prevalence of CNV in diarrheic dogs varies considerably, ranging from 1.3% in Guangxi, China [24], to 7.8% in a multi-province Chinese study [1], 3.1% in South Korea [3], 4.4% in a European multi-country survey [2], and as high as 23% in Portugal [6]. This variability is likely attributable to differences in geographic location, sampling period, diagnostic methods (e.g., conventional RT-PCR vs. real-time RT-PCR), and the health status of the sampled population (e.g., kennel vs. household dogs). Notably, a study in Greece failed to detect CNV in any of 201 dogs, despite using both conventional and SYBR-Green real-time RT-PCR, suggesting that CNV may be absent or circulating at very low levels in certain regions [28]. Similarly, a preliminary investigation in Brazil found no CNV RNA in 30 diarrheic puppies, although 76% were positive for canine parvovirus-2, indicating that other enteric pathogens may be more prevalent in that specific population [32]. Co-infections with other enteric viruses are common. A study in Italy found that CNV (GIV.2) was detected alongside canine coronavirus, canine parvovirus, and canine adenovirus type 1 [26]. In Shanghai, China, canine kobuvirus-positive samples showed co-infection rates with CNV of 0% in one study [27], while a metatranscriptomic analysis of the canine fecal virome in Gansu, China, identified CNV as one of five pathogenic viruses detected, alongside astrovirus, dicipivirus, vesivirus, and rotavirus [25]. These findings underscore the complex polymicrobial nature of canine gastroenteritis and the need for comprehensive diagnostic panels.

The zoonotic potential of CNV is a topic of significant public health interest, given the close and often intimate contact between humans and their pet dogs. Several lines of evidence support the possibility of cross-species transmission. First, CNV VLPs from both GIV and GVI genogroups bind to HBGAs, the same receptors used by HuNoVs [31]. Second, serological studies have detected antibodies against GVI CNV in humans, with a significantly higher seroprevalence in small animal veterinarians (22.3%) compared to the general population (5.8%), suggesting occupational exposure [13]. Third, HuNoV RNA and antibodies have been detected in dogs, and canine gastrointestinal tissues can bind multiple HuNoV genotypes in vitro, indicating that dogs could serve as potential reservoirs or sentinels for human strains [30]. The most compelling evidence for human-to-dog transmission came from a study in Thailand, where recombinant norovirus GII.Pe-GII.4 Sydney, a strain that caused a global pandemic in humans, was detected in dogs with diarrhea living in the same household as infected children [29]. Whole-genome sequencing confirmed the near-identity of the canine and human viruses, strongly suggesting a zoonotic event. Conversely, a study in Costa Rica detected HuNoV GII.4 strains in dogs, pigs, cows, and humans, further supporting the concept of zoo-anthropozoonotic circulation [34]. The World Health Organization (WHO) has recognized norovirus as a priority pathogen for vaccine development, and the potential for animal reservoirs to contribute to the emergence of new human strains adds urgency to this effort [22]. The Centers for Disease Control and Prevention (CDC) also monitors norovirus diversity through networks like CaliciNet, which could be expanded to include animal strains to better assess zoonotic risk [41].

Epidemiology and Prevalence of Canine Norovirus Infections

The elucidation of the epidemiological landscape of canine norovirus (CNV) infection is foundational to understanding its global distribution, transmission dynamics, clinical significance, and potential public health implications. Since the initial identification and characterization of CNV in a diarrheic pup in Italy in 2007 [8], a growing body of surveillance studies, cross-sectional surveys, outbreak investigations, and serosurveys has progressively revealed that CNV is a widely disseminated enteric pathogen in canine populations across multiple continents. However, the reported prevalence rates exhibit considerable heterogeneity, influenced by factors such as geographic region, study population (e.g., diarrheic versus healthy dogs, shelter versus pet populations), diagnostic methodology (molecular detection versus serology), sampling timeframe, and the genogroup/genotype under investigation. Understanding this complex epidemiological picture requires a granular examination of the available evidence, moving beyond simple prevalence figures to consider the biological and ecological drivers of CNV circulation.

Global Emergence and Disparate Prevalence Rates

The earliest molecular epidemiological investigations following the discovery of CNV provided immediate evidence of substantial viral circulation within specific cohorts. In a pivotal Portuguese study conducted between 2007 and 2011, Mesquita and Nascimento [6] documented a remarkably high molecular prevalence of 23% (60/256) in fecal samples from dogs across Portugal. This study was among the first to establish CNV as an endemic infection in a canine population, with all sequenced strains exhibiting high nucleotide identity (98–100%) to the initially described Portuguese CNV strain. This finding suggested a homogenous, dominant viral lineage circulating within that geographic region during that period. Conversely, subsequent studies in other regions reported markedly lower prevalence rates, highlighting significant geographical variation. In China, a large-scale surveillance effort using a novel quadruplex RT-qPCR on 1,688 clinical samples from pet hospitals in Guangxi province (2022–2024) detected CNV in only 1.30% (22/1688) of samples [24]. Similarly, an earlier molecular survey across three Chinese provinces from 2017 to 2019 using conventional RT-PCR identified CNV in 7.8% (21/268) of canine diarrheic fecal samples [1], a figure substantially lower than the Portuguese study but higher than the Guangxi province survey. This discrepancy may reflect differences in the clinical status of the sampled population (all diarrheic in the earlier Chinese study [1] versus a mixed population in the later one [24]), the sensitivity of the diagnostic assays employed, or genuine temporal and geographic fluctuations in virus prevalence. In South Korea, the first identification of CNV revealed a molecular prevalence of 3.1% (14/459) in fecal samples collected from small animal clinics and shelters, with all isolated strains phylogenetically clustering within genogroup GIV [3]. Other European surveys have shown intermediate prevalence rates. Screening of young dogs from multiple European countries identified CNV in 4.4% (13/294) of animals with signs of enteritis, while CNV was notably absent in a small cohort of healthy dogs (0/42) [2]. In Italy, a molecular screening of 284 dogs conducted between 2019 and 2021 detected CNV (specifically norovirus GIV.2) as part of a mixed infection in a subset of animals [26]. In Japan, between 2007 and 2014, CNV was found in approximately 2% (2/97) of diarrheic dogs [11]. In Greece, an intensive molecular survey of 201 domestic dogs using both conventional and SYBR-Green real-time RT-PCR failed to detect CNV in any sample [28], suggesting either extremely low prevalence or the absence of the specific genotypes targeted by the used primers in that population at that time. In Brazil, a study in Cuiabá did not detect CNV RNA in 30 diarrheic puppies [32], while a more comprehensive metagenomic study from the Brazilian Amazon identified the first detection of canine norovirus GVII in the country [16]. These negative or low-prevalence findings are as informative as positive detections, as they underscore that CNV is not uniformly present across all canine populations and suggest that its circulation may be highly focal or influenced by specific epidemiological conditions, such as high-density housing.

Seroprevalence: A Window into Historical Exposure

Molecular detection of viral RNA provides a snapshot of active or recent shedding, which is often transient. Serological surveys, by detecting anti-CNV IgG antibodies, offer a more comprehensive measure of cumulative lifetime exposure and reveal a far higher prevalence of infection than molecular studies alone. This distinction is critical: many infected dogs may clear the virus rapidly, shedding at levels below the detection limit of RT-PCR or for a duration too brief to be captured in a cross-sectional fecal sample. The most compelling serological evidence comes from the United Kingdom, where Caddy et al. [4] screened canine serum samples for antibodies against virus-like particles (VLPs) representing three different CNV strains. They found that 38.1% of samples collected between 1999 and 2001 were seropositive, but this figure rose dramatically to 60.1% in samples collected from 2012 to 2013. This statistically significant increase (p<0.001) over time suggests that CNV strains were becoming more widespread in the UK dog population, possibly reflecting viral evolution, increasing diagnostic awareness, or changes in dog husbandry and population density. Furthermore, the study revealed that approximately two-thirds of seropositive dogs had antibodies to a single CNV strain, while the remaining third had antibodies to multiple strains, indicating the circulation of antigenically diverse viruses within the same population [4]. A large pan-European serosurvey, testing 510 serum samples from dogs in 14 European countries, confirmed that seropositive dogs were found across the continent, underscoring the widespread nature of CNV exposure [44]. In South Korea, seroprevalence was estimated at 15.9% (68/427) [3], a figure substantially higher than the molecular detection rate in the same country (3.1%), aligning with the paradigm that serology reveals a much larger infected population.

Molecular Epidemiology and Genogroup Distribution

The epidemiological picture is further complicated by the genetic diversity of CNV, which has implications for cross-species transmission, immune evasion, and diagnostic detection. Canine noroviruses are classified into genogroups GIV, GVI, and GVII based on the complete VP1 capsid protein amino acid sequence [21]. Studies from various parts of the world have revealed distinct patterns in the circulation of these genogroups. In the United States, genomic analyses of canine noroviruses revealed the circulation of GIV.2, GVI.1, and GVI.2 strains [18]. In Portugal, the initially dominant strains were found to be GVI.2 [6]. In Italy, Bodnar et al. [2] identified a novel GVI genotype (tentatively designated GVI.3) in addition to GVI.1 and GVI.2 strains, showcasing the ongoing genetic evolution and heterogeneity of CNV in carnivores. Importantly, this study also identified a feline GVI strain that was closely related to canine GVI.2 strains, suggesting the potential for unrestricted circulation and interspecies transmission between dogs and cats [2, 12]. Indeed, feline noroviruses belonging to GIV and GVI have been reported, with some feline strains being genetically closest to canine GVI.2 NoVs, indicating a shared viral pool and possible recombination events at the ORF1-ORF2 junction [12]. The first complete genome of a GVI.2 strain from mainland China (strain Dog/M9/18/CH) was generated by Ma et al. [1], who found it was closely related to USA GVI.2 strains, demonstrating the global interconnectedness of CNV lineages. More recently, a fox norovirus was identified in China that clustered phylogenetically with canine GVII strains, further expanding the host range and genetic diversity of noroviruses in carnivores [9]. The detection of GVII in dogs is less frequent but has been reported in Brazil [16] and China [9], suggesting these viruses may be emerging or have been previously overlooked.

Outbreak Dynamics, Seasonality, and Transmission

The epidemiological features of CNV outbreaks bear a striking resemblance to those of human norovirus infections. Mesquita and Nascimento [5] documented a classic outbreak of acute gastroenteritis in a Portuguese kennel following the introduction of imported dogs from Russia. The virus disseminated rapidly, infecting all dogs within the kennel in two days. The incubation period was calculated to be less than 48 hours, the diarrheal disease was self-limiting, and viral shedding persisted for less than 7 days [5]. This rapid transmission, short incubation, and self-limiting nature are hallmarks of human norovirus [20, 46] and highlight the highly contagious nature of CNV in a confined setting. Seasonality is another key epidemiological feature shared with human norovirus. Mesquita and Nascimento [6] found the highest rate of viral fecal shedding in dogs during the winter months in Portugal. This mirrors the well-documented winter seasonality of human norovirus outbreaks [36, 47] and may be driven by similar factors such as increased time spent indoors in close proximity, environmental stability of the virus under cooler, humid conditions, and potential host physiological changes. Transmission in dogs is primarily fecal-oral, but the rapid spread within kennels also points to the potential for fomite and environmental transmission, given the virus's stability on surfaces [45]. Co-infections appear to be a common epidemiological feature. Studies have frequently reported CNV in mixed infections with other enteric pathogens, including canine parvovirus (CPV-2), canine coronavirus (CCoV), canine astrovirus (CAstV), and canine distemper virus (CDV) [26, 27, 34]. This complicates the attribution of disease solely to CNV, as it may act synergistically with other pathogens to exacerbate clinical signs [24].

Age-Related Susceptibility and Zoonotic Considerations

Epidemiological evidence suggests that young dogs are at increased risk for CNV infection, a pattern consistent with many enteric viral infections. In the initial Italian study, CNV was identified in a pup with enteritis [8]. Similarly, the pan-European study by Bodnar et al. [2] specifically screened young dogs. The lack of age-stratified data in many studies limits a precise quantification of this risk, but the finding of high seroprevalence in adult dogs indicates that infection likely occurs early in life [4]. The close genetic and antigenic relationship between CNV and human noroviruses has raised significant public health concerns regarding zoonotic transmission. Serological studies have detected antibodies against GVI norovirus in human populations, with a significantly higher seroprevalence in small animal veterinarians (22.3%) compared to the general population (5.8%) [13]. This suggests that occupational exposure to dogs increases the risk of encountering CNV, indicating that dogs may serve as a reservoir for human infection. Furthermore, human norovirus GII.4 strains have been detected in dogs, and canine tissues have been demonstrated to bind human norovirus VLPs in vitro, providing evidence for potential human-to-dog transmission and the possibility of a two-way zoonotic exchange [29, 30, 34]. These findings underscore the intricate and bidirectional nature of norovirus transmission at the human-animal interface and warrant continued surveillance as mandated by global health authorities like the World Health Organization (WHO) for emerging zoonoses.

Clinical Manifestations and Host Immune Response

The clinical presentation of canine norovirus (CNV) infection is characterized by a spectrum of disease severity, ranging from subclinical carriage to acute gastroenteritis (AGE). Understanding the full breadth of the clinical manifestations is essential for differential diagnosis, while elucidation of the host immune response provides critical insights into pathogenesis, protection, and the potential for zoonotic transmission. While CNV has been identified as a cause of enteritis in dogs, its exact pathogenic role can be confounded by frequent co-infections with other enteric viruses and the existence of asymptomatic shedding.

Clinical Manifestations of Canine Norovirus Infection

Acute Gastroenteritis and Outbreak Dynamics The most definitive evidence linking CNV to clinical disease comes from outbreak investigations. In a notable kennel outbreak in Portugal, the introduction of imported dogs from Russia led to an episode of acute gastroenteritis that spread rapidly among all dogs within 48 hours. The incubation period was less than 48 hours, and the diarrheal disease was self-limiting, with viral shedding persisting for less than seven days [5]. This temporal pattern closely mirrors that of human norovirus infections, which are renowned for their abrupt onset, short incubation period, and rapid transmission in closed settings. The epidemiological features of this outbreak demonstrated the highly contagious nature of CNV and its ability to cause explosive outbreaks in kennel environments, where population density and fecal-oral transmission routes are amplified [5].

Further evidence for the pathogenic potential of CNV comes from a comprehensive study of dogs with and without diarrhea, which revealed a stark contrast in prevalence. CNV was detected in 40% of dogs with diarrhea compared to only 9% of dogs without diarrhea, strongly suggesting a causative association [14]. This study was instrumental in establishing CNV as a significant enteric pathogen rather than an incidental finding. The clinical signs described in affected animals typically include watery or loose stools, occasional vomiting, and lethargy, with the disease being generally self-limiting in immunocompetent adult dogs. Young puppies, however, may be at higher risk for more severe or prolonged disease [8, 17].

Subclinical Infections and Asymptomatic Carriage Despite the strong association with diarrhea, a substantial proportion of CNV infections are subclinical. Detection of CNV in asymptomatic dogs has been reported in numerous studies across the globe. For instance, in a study from South Korea, while CNV was detected in 3.1% of fecal samples, the clinical status of the animals was not always indicative of infection [3]. Similarly, in Greece, a large-scale screening of domestic dogs found no CNV-positive samples at all, regardless of the presence or absence of gastroenteritis symptoms [28]. This highlights the geographic variability in CNV prevalence and its clinical impact. The phenomenon of asymptomatic shedding is a critical factor in the epidemiology of CNV, as healthy carriers can serve as a silent reservoir for virus transmission within kennels, shelters, and multi-dog households, complicating disease control efforts.

Co-infections and Impact on Disease Severity CNV is rarely found as a sole infectious agent in clinical cases. Instead, it frequently co-occurs with other canine enteric pathogens, which can exacerbate the severity of clinical disease. In a large-scale study using a novel quadruplex RT-qPCR assay, the positivity rates of CNV were found to be relatively low at 1.30% (22/1688) in clinical samples, while co-infections with canine coronavirus (CCoV), canine respiratory coronavirus (CRCoV), and canine adenovirus type 2 (CAV-2) were more prevalent [24]. In a study from Italy, CNV (specifically norovirus GIV.2) was detected alongside other viruses such as canine parvovirus type 2 and CCoV in a substantial number of cases [26]. Similarly, in China, co-infections of CNV with other enteric viruses like canine kobuvirus and canine astrovirus have been documented [27]. The presence of multiple pathogens can lead to a more complex clinical picture, making it difficult to attribute specific symptoms solely to CNV. It is plausible that CNV acts synergistically with other pathogens, potentially disrupting the intestinal epithelial barrier and mucosal immunity, thereby predisposing the host to more severe infections by other agents.

Host Immune Response to Canine Norovirus

The host immune response to CNV is a complex interplay of innate and adaptive mechanisms, with several features bearing close resemblance to human norovirus immunity. Key aspects include serological responses, the role of histo-blood group antigens (HBGAs) as attachment factors, and the protective role of the interferon system.

Seroprevalence and Evidence of Widespread Exposure Serological studies have provided powerful evidence for widespread exposure to CNV in the global dog population. In a landmark study across 14 European countries, anti-CNV IgG antibodies were detected in dogs from all regions, indicating that the virus is enzootic across Europe [44]. A more detailed investigation in the United Kingdom revealed a significant increase in seroprevalence over time. Between 1999–2001, 38.1% of canine serum samples were seropositive for CNV, but this figure rose to 60.1% in samples collected between 2012–2013 [4]. This temporal increase strongly suggests that CNV strains are becoming more widespread and that the virus is establishing itself as a common infection within the canine population. Importantly, the UK study also identified seropositivity to multiple different CNV strains, and approximately one-third of seropositive dogs had antibodies to two or three distinct strains, indicating repeated exposure to antigenically diverse viruses [4]. The development of robust IgG antibody responses, particularly to the major capsid protein VP1, is a hallmark of infection and the primary basis for serological surveillance using virus-like particle (VLP)-based enzyme immunoassays [3, 44].

The Role of Histo-Blood Group Antigens (HBGAs) A critical breakthrough in understanding norovirus host-pathogen interactions was the discovery that CNV utilises HBGAs as attachment factors, similar to human noroviruses. GIV and GVI canine noroviruses specifically bind to α1,2-fucose-containing H and A antigens of the HBGA family [31]. This interaction was demonstrated using CNV VLP binding to canine saliva and intestinal tissue sections. The expression of these HBGAs is genetically determined, suggesting that individual dogs may have inherent susceptibility or resistance to CNV infection based on their HBGA phenotype. In humans, secretor status (determined by the FUT2 gene) is a major determinant of susceptibility to many norovirus genotypes, and a similar mechanism is likely at play in dogs [38]. This implies that the canine population is not uniformly susceptible to CNV, and genetic polymorphism at HBGA loci could shape the epidemiology and clinical impact of the virus.

Adaptive Immune Response and Potential for Zoonotic Exposure A particularly compelling and concerning aspect of CNV immunology is the evidence for cross-species immune recognition between canine and human noroviruses. Dogs have been shown to produce antibodies against human norovirus (HuNoV). In one study, 43 out of 325 canine serum samples (13.2%) contained antibodies that reacted with HuNoV virus-like particles, and the seroprevalence in dogs mirrored that seen in the human population for different HuNoV genotypes [30]. This suggests that dogs are not only exposed to CNV but also to HuNoV, potentially through reverse zoonosis (human-to-dog transmission). Indeed, a study in Thailand reported the detection of a recombinant human norovirus GII.Pe-GII.4 Sydney strain in dogs that were in direct contact with infected children, providing strong molecular evidence for human-to-canine transmission [29].

Conversely, there is mounting evidence that CNV can infect humans, particularly those in close occupational contact with dogs. A seminal serosurvey of small animal veterinarians in Portugal found IgG antibodies against GVI canine norovirus in 22.3% of veterinarians compared to only 5.8% of the general population control group [13]. This statistically significant difference indicates an elevated risk of exposure for veterinary professionals, consistent with zoonotic transmission. These findings are supported by studies in Costa Rica, where human norovirus GII.4 strains were detected in dogs, and canine norovirus strains were detected in humans, suggesting a two-way street of potential zoo-anthropozoonosis [34]. The ability of CNV to bind to human HBGAs further reinforces its zoonotic potential, as the molecular machinery for attachment to human cells appears to be present [31].

Cellular and Innate Immune Mechanisms While the humoral (antibody) response is well-characterized, less is known about the cellular immune response to CNV in dogs. However, insights can be drawn from murine norovirus (MNV) and human norovirus models. In mice, norovirus infection is controlled by both innate and adaptive immunity. Type I and III interferons (IFN) are critical for controlling acute infection. Interferon-induced JAK/STAT signaling pathways are activated in response to norovirus replication, and viral replication is restricted by these signaling cascades in human intestinal epithelial cells [40]. Furthermore, the intestinal microbiota plays a complex role, regionally modulating the type III interferon response through bile acid metabolism, thereby influencing norovirus infection along the intestinal tract [39]. In dogs, it is likely that similar interferon-mediated antiviral states are crucial for limiting CNV replication and spread.

A particularly fascinating discovery relevant to norovirus pathogenesis is the tropism for tuft cells. In mice, tuft cells, a rare type of intestinal epithelial cell, express the CD300lf receptor for MNV and are the primary target cell for persistent infection. Importantly, tuft cell proliferation is promoted by type 2 cytokines (IL-4 and IL-25), and immune responses that stimulate these cytokines actually promote norovirus infection [43]. This suggests that the host immune response can be co-opted by the virus to enhance its own replication. While the receptor for CNV has not been definitively identified, this paradigm highlights the sophisticated interplay between the virus and the host's immune environment. The ability of norovirus to evade and manipulate host stress responses, such as the shut-off of host translation and the redistribution of the RNA-binding protein G3BP1, allows the virus to replicate efficiently while avoiding the formation of antiviral stress granules [42]. These mechanisms are likely conserved across norovirus genogroups, including canine strains.

In conclusion, CNV infection elicits a robust and complex immune response characterized by seroconversion to capsid proteins, likely driven by HBGA-dependent attachment. The high seroprevalence rates, reaching up to 60% in some canine populations, indicate widespread and repeated exposure. Critically, the immunological data strongly suggest bidirectional transmission potential between dogs and humans, positioning CNV not only as a canine enteric pathogen but also as a potential zoonotic agent with public health implications. The WHO has identified norovirus as a priority for vaccine development [22], and understanding the immune correlates of protection in dogs may aid the development of strategies to protect both animal and human health.

Diagnostic Approaches for Canine Norovirus Detection

The accurate and timely detection of canine norovirus (CNV) is paramount for understanding its epidemiology, clinical impact, and potential zoonotic implications. As a leading veterinary researcher, I must emphasize that the diagnostic landscape for CNV has evolved considerably from early research tools to sophisticated, high-throughput, molecular methodologies. The inherent challenges of CNV detection, including its genetic diversity across genogroups GIV, GVI, and GVII, the frequent occurrence of co-infections with other enteric pathogens, and the often-subclinical nature of shedding, necessitate a multi-pronged diagnostic strategy. This section provides an exhaustive analysis of the current and emerging diagnostic approaches, ranging from conventional molecular detection to advanced multiplex platforms and serological surveillance tools.

Molecular Detection of CNV RNA

The cornerstone of CNV diagnosis lies in the detection of viral RNA, primarily through reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variant (RT-qPCR). These methods offer the requisite sensitivity and specificity for identifying actively shedding animals, even in the absence of clinical signs.

Conventional Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Conventional RT-PCR has been the foundational tool for the initial discovery and molecular characterization of CNV, particularly for amplifying conserved regions of the RNA-dependent RNA polymerase (RdRp) gene and the capsid VP1 gene. Early epidemiological studies, such as those identifying CNV in Italy (2007) [8] and subsequently in Portugal, Greece, and the United States, relied heavily on this technique. For instance, Mesquita et al. (2010) utilized RT-PCR targeting the RdRp gene to detect CNV in 40% of dogs with diarrhea, revealing a tentative new genogroup [14]. Similarly, Ma et al. (2021) employed RT-PCR on 268 diarrheic samples from China, achieving a 7.8% positivity rate and enabling phylogenetic classification into GVI.1, GVI.2, and GIV.2 clades [1]. This approach was also instrumental in the first detection of CNV in South Korea, where Lyoo et al. (2018) used RT-PCR to identify GIV strains in 3.1% of fecal samples [3]. The utility of conventional RT-PCR extends to generating amplicons for Sanger sequencing, which is critical for genotyping and evolutionary studies. However, its limitations in throughput and quantitative capacity have largely been superseded by real-time methods for routine surveillance.

Quantitative Real-Time RT-PCR and Multiplex Assays

The advent of real-time RT-PCR (RT-qPCR) has revolutionized CNV diagnostics, offering enhanced sensitivity, specificity, and the ability to quantify viral loads. This is particularly important given the typically low viral loads observed in canine feces and the brief shedding period of less than seven days during acute infection [5]. The design of robust RT-qPCR assays targets highly conserved regions to ensure detection across diverse genotypes. Shi et al. (2024) [24] established a quadruplex RT-qPCR that simultaneously detects CNV (targeting the RdRp gene) alongside canine coronavirus (CCoV), canine respiratory coronavirus (CRCoV), and canine adenovirus type 2 (CAV-2). This assay demonstrated exceptional analytical performance, with a limit of detection (LOD) of 1.0 × 10² copies/reaction for each target, including CNV. Crucially, it exhibited no cross-reactivity with other common canine viruses and achieved near-perfect agreement (>99.53%) with reference monoplex assays, highlighting its suitability for routine clinical screening [24]. The intra-assay variability (0.19–1.31%) and inter-assay variability (0.10–0.88%) further underscore the repeatability essential for research-grade and diagnostic applications. Studies in Greece, while failing to detect CNV in 201 dogs using conventional and SYBR-Green real-time RT-PCR, validated the superior sensitivity of the real-time approach for other enteric viruses like astrovirus and sapovirus, an attribute directly applicable to CNV surveillance [28]. The use of probe-based (TaqMan) assays in such multiplex formats is generally preferred over SYBR-Green for their added specificity, as they reduce the risk of false positives from non-specific amplification products.

Nested and Semi-Nested RT-PCR for Genotyping

For detailed molecular characterization, particularly when viral loads are low, nested or semi-nested RT-PCR strategies are employed. These approaches increase sensitivity by using two rounds of amplification, as demonstrated in the characterization of CNV strains from southern Italy, where a semi-nested RT-PCR was used to amplify and sequence the RdRp region from samples with low viral titers [2]. This approach is critical for obtaining the genomic material necessary to investigate recombination events, a major driver of norovirus diversity, especially at the ORF1-ORF2 junction [18, 23]. Chhabra et al. (2020) validated a single-step RT-PCR assay for dual genotyping (capsid and polymerase) of human GI and GII noroviruses, a principle that can be adapted for canine strains to improve classification of emerging recombinants [41].

Advanced Sequencing and Metagenomics

The most comprehensive diagnostic approach is viral metagenomics, which employs next-generation sequencing (NGS) to characterize the entire virome of a sample without prior knowledge of its composition. This technique has proven invaluable in detecting CNV in complex fecal matrices and in identifying novel strains. Gao et al. (2025) used metatranscriptomic analysis of pooled canine fecal samples from China to identify 16 viral genera, including CNV, and to assess the broader viral ecosystem [25]. Similarly, Deus et al. (2024) applied shotgun metagenomics to investigate viral diversity in dogs with acute gastroenteritis in the Brazilian Amazon, achieving the first detection of CNV GVII in Brazil and reconstructing twelve complete or nearly complete viral genomes [16]. While not suitable for routine point-of-care testing due to cost and bioinformatics requirements, metagenomics provides an unparalleled view of CNV genetic diversity, co-infections, and potential zoonotic threats. It has been instrumental in detecting human norovirus genotypes (e.g., GII.Pe-GII.4) in dogs, suggesting cross-species transmission events [29].

Serological Approaches for CNV Detection

While molecular detection indicates active or recent infection, serological assays detect past exposure by measuring antibodies against CNV. This is essential for population-level surveillance and understanding the prevalence of infection within a geographic area.

Virus-Like Particle (VLP)-Based Enzyme-Linked Immunosorbent Assay (ELISA)

The development of serological tools for CNV has relied heavily on recombinant virus-like particles (VLPs) produced by expressing the VP1 capsid protein in baculovirus or other expression systems. These VLPs mimic the antigenic structure of the native virus without being infectious. Caddy et al. (2013) used VLPs from three different CNV strains to screen 396 canine serum samples from the UK, revealing a high seroprevalence (38.1% from 1999-2001, rising to 60.1% in 2012-2013) and demonstrating the presence of multiple circulating strains [4]. Mesquita et al. (2014) employed a similar VLP-based ELISA to test sera from 14 European countries, confirming widespread seropositivity for CNV across the continent [44]. This methodology has also been adapted for human serosurveys. Mesquita et al. (2013) found that 22.3% of small animal veterinarians had antibodies to genogroup VI CNV, compared to only 5.8% of the general population controls, suggesting an occupational risk of zoonotic exposure [13]. The binding of CNV VLPs to histo-blood group antigens (HBGAs), particularly α1,2-fucose-containing H and A antigens, has been confirmed in vitro using ELISA-based binding assays, providing crucial insights into the virus-host interaction and potential mechanisms of susceptibility [31].

Emerging and Point-of-Care Diagnostic Technologies

The development of rapid, field-deployable diagnostics remains a priority, especially for outbreak investigations and resource-limited settings.

Aptamer-Based Biosensors

A promising frontier is the use of aptamer-conjugated nanomaterials for ultrasensitive colorimetric detection. Weerathunge et al. (2019) developed a NanoZyme aptasensor for murine norovirus (a surrogate for human norovirus) that achieved a limit of detection of 3 viruses per assay (30 viruses/mL) in just 10 minutes [48]. This technology combines the catalytic activity of gold nanoparticles (nanozymes) with the specificity of aptamers, producing a colorimetric signal proportional to virus concentration. While not yet validated for CNV in canine matrices, the principles are directly translatable. Such platforms could revolutionize the detection of CNV in fecal samples during acute outbreaks, enabling rapid containment measures.

Cultivation in Human Intestinal Enteroids

Although not a diagnostic test per se, the recent cultivation of human norovirus in stem cell-derived human intestinal enteroids (HIEs) has significant implications for CNV research [49, 52]. This system allows for functional studies of viral infectivity, assessment of neutralizing antibodies, and evaluation of disinfectants. For CNV, the adaptation of HIE technology, or potentially canine intestinal enteroids, could provide a gold-standard method for determining viral viability, which is not possible with RT-PCR alone. This is critical because RNA detection can overestimate infectious risk, as viral RNA can persist long after infectivity is lost [45]. The HIE system has already been used to evaluate inactivation strategies for human norovirus, demonstrating that chlorine is effective while alcohols are not [52]. Applying these functional assays to CNV would be a major advance.

Diagnostic Challenges and Strategic Considerations

Despite these advances, several challenges persist. The genetic diversity of CNV within genogroups GIV, GVI, and GVII, including the identification of a tentative third GVI genotype [2], demands that diagnostic assays be designed with broad reactivity. False negatives can occur if primers or probes do not match the target sequence. The use of degenerate primers or multiplex panels targeting multiple conserved loci, such as the RdRp gene, is therefore recommended. Additionally, the short duration of fecal shedding (<7 days) and the intermittent nature of excretion in subclinical carriers means that a single negative test does not rule out infection [5]. Repeat sampling or the inclusion of serological testing may be necessary for a complete assessment.

From a public health perspective, the CDC and World Health Organization (WHO) recognize noroviruses as a leading cause of acute gastroenteritis in humans [19, 50, 51]. The detection of CNV in dogs, coupled with serological evidence of human exposure [13] and the presence of human norovirus strains in canine feces [29], underscores the need for integrated "One Health" surveillance. Veterinary clinicians should consider CNV infection in cases of acute gastroenteritis, particularly in kennels or multi-dog households where outbreaks occur [5]. The adoption of validated molecular assays, such as the quadruplex RT-qPCR developed by Shi et al. [24], should be encouraged in diagnostic laboratories to facilitate rapid etiological diagnosis and inform management strategies, including isolation and hygiene protocols. Continued development of rapid antigen tests and point-of-care devices will further enhance our ability to monitor and control this emerging enteric pathogen.

Molecular Characterization of Canine Norovirus Genomes (RdRp, VP1, VP2)

The genomic architecture of canine norovirus (CNV) conforms to the canonical norovirus organization of a positive-sense, single-stranded RNA genome of approximately 7.5–8.2 kb, encompassing three open reading frames (ORFs). ORF1 encodes a large polyprotein that is post-translationally cleaved into six non-structural proteins, including the RNA-dependent RNA polymerase (RdRp). ORF2 encodes the major capsid protein VP1, while ORF3 encodes the minor structural protein VP2. Molecular characterization of these three genomic regions, RdRp, VP1, and VP2, has proven indispensable for deciphering the phylogenetic relationships, evolutionary dynamics, and functional biology of canine noroviruses, and has underpinned the establishment of a robust classification framework that distinguishes CNV strains from those infecting humans and other animal species [8, 14, 21].

The RNA-Dependent RNA Polymerase (RdRp) Gene

The RdRp gene, situated within ORF1, encodes the viral replicase responsible for genome replication and transcription. This region contains the canonical GLPSG amino acid motif, a hallmark of norovirus polymerases that is essential for catalytic activity. Mesquita and Nascimento (2012) first demonstrated that all CNV strains identified in Portuguese dogs harbored this conserved motif, confirming the authenticity of the polymerase sequences [5, 6]. The RdRp gene has been a primary target for molecular detection and phylogenetic classification of CNV, largely because it is sufficiently conserved for primer design yet variable enough to discriminate between genogroups and polymerase types (P-types). Shi et al. (2024) exploited this conservation to design a quadruplex RT-qPCR targeting the CNV RdRp gene for simultaneous detection alongside canine coronavirus, canine respiratory coronavirus, and canine adenovirus type 2, achieving high sensitivity with a limit of detection of 1.0 × 10² copies per reaction [24].

Phylogenetic analysis of partial RdRp sequences (typically ~300–500 bp fragments) has revealed that CNV strains segregate into three distinct genogroups, GIV, GVI, and GVII, with additional subdivision into polymerase types. The initial characterization by Martella et al. (2008) identified a novel canine calicivirus with a RdRp sequence that was genetically related to a lion norovirus strain, laying the groundwork for subsequent genogroup assignments [8]. Later, Mesquita et al. (2010) demonstrated that CNV strains from Portugal constituted a tentative new genogroup (later designated GVI) based on RdRp divergence from previously known human and animal noroviruses [14]. Ma et al. (2021) performed a comprehensive molecular survey of CNV in mainland China, amplifying and sequencing the RdRp fragments of 21 positive samples. Their phylogenetic analysis revealed a predominance of GVI.2 strains (18 of 21), with minor contributions from GVI.1 (2 strains) and GIV.2 (1 strain). Complete RdRp gene sequences obtained for four GVI.2 strains further confirmed their close relationship with previously characterized USA GVI.2 strains, extending our understanding of the global distribution of this polymerase type [1].

The RdRp gene is also critical for identifying recombinant norovirus strains. Since recombination events frequently occur at the ORF1-ORF2 junction, the polymerase genotype often differs from the capsid genotype, leading to the designation of dual types (e.g., GII.Pe-GII.4). While such recombination is well-documented in human noroviruses, evidence in canine noroviruses is growing. Bodnar et al. (2017) provided compelling evidence for recombination among GVI strains, noting that strain 5010/2009/ITA displayed a unique phylogenetic position in the RdRp region that was discordant with its VP1-based classification, suggesting a possible recombination event involving a GVI.2-like polymerase and a novel GVI.3-like capsid [2]. More recently, Charoenkul et al. (2020) reported the detection of a recombinant human norovirus GII.Pe-GII.4 Sydney strain in dogs in Thailand, with whole-genome sequencing confirming that the canine-derived virus was nearly identical to contemporaneous human strains, providing strong evidence for human-to-canine transmission [29]. This finding underscores the potential for norovirus polymerase genes to serve as molecular markers for cross-species transmission events and highlights the importance of dual typing (polymerase and capsid) in CNV molecular epidemiology.

The Major Capsid Protein (VP1) Gene

VP1, encoded by ORF2, is the major structural protein that self-assembles into virus-like particles (VLPs) and mediates host cell attachment via interactions with histo-blood group antigens (HBGAs). The VP1 gene is the primary determinant of norovirus genogroup and genotype classification, as established by the international norovirus classification-working group [21]. According to the updated 2019 classification scheme, CNV strains are assigned to genogroup IV (genotype 2), genogroup VI (genotypes 1, 2, and 3), and genogroup VII (genotype 1) based on complete VP1 amino acid sequence diversity, using the criterion of >2× standard deviation in pairwise distances to define distinct genotypes [21].

The VP1 protein of CNV comprises two major domains: the shell (S) domain, which forms the inner core of the capsid, and the protrusion (P) domain, which extends outward and contains the P1 and P2 subdomains. The P2 subdomain is the most variable region of VP1 and harbors key determinants of HBGA binding specificity and antigenicity. Caddy et al. (2014) performed a seminal functional characterization of CNV VP1, demonstrating that VLPs derived from both GIV.2 and GVI.2 strains bind specifically to α1,2-fucose-containing H and A HBGAs, a binding pattern strikingly similar to that of human GI and GII noroviruses. Using synthetic oligosaccharides, ELISA-based binding assays, and immunohistochemistry on canine tissues, they identified α1,2-fucose as a critical attachment factor. Blockade studies, cell lines expressing HBGAs, and enzymatic removal of candidate carbohydrates confirmed the specificity of this interaction [31]. This discovery has profound implications for understanding norovirus evolution and zoonotic potential, as it suggests that CNV shares the same host attachment factors as human noroviruses, thereby raising the theoretical possibility of cross-species infection.

Sequence analysis of the VP1 gene has also revealed the remarkable genetic heterogeneity of CNV, with strains exhibiting substantial divergence even within the same genogroup. Bodnar et al. (2017) characterized the 3.4 kb 3′-terminal genome region (encompassing VP1 and VP2) of four CNV strains from Italy. Strains 63.15/2015/ITA and FD53/2007/ITA were closely related to the GVI.2 prototype strain C33/Viseu/2007/PRT (97.4–98.6% nucleotide and 90.3–98.6% amino acid identity in VP1). Strain FD210/2007/ITA showed highest identity to the GVI.1 strain Bari/91/2007/ITA (88.0% nucleotide and 95.0% amino acid identity). Remarkably, strain 5010/2009/ITA displayed only 66.6–67.6% nucleotide and 75.5–81.6% amino acid identity to the GVI.1 strains and even lower identity to feline GVI strains. Based on these data and the established classification criteria, the authors proposed that 5010/2009/ITA represents a third genotype within GVI (GVI.3), thereby expanding our understanding of the genetic diversity of noroviruses in carnivores [2]. The World Organisation for Animal Health (WOAH) has recognized the emergence of such novel genotypes as a critical area for surveillance, particularly given the potential for interspecies transmission among companion animals.

The VP1 gene has also been instrumental in documenting the circulation of human norovirus genotypes in dogs. In Costa Rica, Matamoros et al. (2023) detected human norovirus GII.4 VP1 sequences in canine fecal samples, along with canine GVI.P1 strains, providing serological and molecular evidence for the zoo-anthropozoonotic potential of human GII.4 strains [34]. Similarly, Charoenkul et al. (2020) identified GII.Pe-GII.4 Sydney VP1 sequences in dogs housed in a Thai kennel where children on the same premises had concurrent gastroenteritis, and whole-genome sequencing confirmed the near-identity of canine and human strains [29]. These findings suggest that dogs may serve as sentinel hosts or potential reservoirs for human norovirus, a concern that has been echoed by the Centers for Disease Control and Prevention (CDC) in their guidelines for norovirus outbreak investigations involving household contacts of infected individuals.

The Minor Structural Protein (VP2) Gene

VP2, encoded by ORF3, is the minor structural protein of noroviruses, located internally within the capsid. Although its function is less well-characterized than that of VP1, VP2 is thought to play a role in capsid stability, genome encapsidation, and modulation of host immune responses. In CNV, the VP2 gene is approximately 600–700 nucleotides in length and exhibits significant sequence diversity that correlates with VP1-based genogroup assignments. Ma et al. (2021) reported the complete VP2 gene sequences of four GVI.2 strains from China, which showed 95.9% nucleotide identity to the only available complete GVI.2 genome at the time, underscoring the relative conservation of VP2 within a genotype [1].

Phylogenetic analyses based on VP2 sequences generally recapitulate the genogroup and genotype relationships established by VP1, but VP2 can provide additional resolution for closely related strains. Ford-Siltz et al. (2019) performed a comprehensive genomic analysis of GIV and GVI noroviruses from the United States, sequencing eight nearly complete genomes including three GVI.1, three GVI.2, and four GIV.2 strains. Their phylogenetic analysis of VP2, together with VP1 and RdRp, revealed distinct clustering patterns that confirmed the separate evolutionary trajectories of animal and human noroviruses. Notably, they identified chimeric GVI/GIV viruses exclusively in animal strains, suggesting that recombination constraints differ between human and canine noroviruses, possibly due to differences in host range or replication kinetics [18]. The VP2 gene has also been implicated in norovirus recombination events. Martino et al. (2015) characterized a novel feline norovirus strain (TE/77-13/ITA) that was genetically closest to canine GVI.2 strains in the VP1 region (81–84% nucleotide identity) but clustered with feline GIV.2 strains in the RdRp region, with the crossover site mapped precisely to the ORF1-ORF2 junction. This recombination event, which involved the exchange of polymerase and capsid genes from different genogroups, was confirmed by analyzing the VP2 region, which cosegregated with VP1 as expected for the 3′-terminal portion of the genome [12].

Evolutionary Dynamics and Classification Implications

The molecular characterization of the RdRp, VP1, and VP2 genes has profoundly influenced our understanding of CNV evolution and classification. Parra (2019) articulated a dual-mechanism model for norovirus diversification, wherein point mutations accumulate in VP1 (antigenic drift) while recombination at the ORF1-ORF2 junction generates novel polymerase-capsid combinations [23]. This model is fully applicable to CNV, where evidence for both mechanisms is accumulating. The high mutation rate characteristic of RNA viruses, coupled with the error-prone nature of RdRp, drives the emergence of new CNV variants over time. Meanwhile, recombination, facilitated by co-infection of the same host with multiple norovirus strains, can generate chimeric viruses with altered tissue tropism, host range, or antigenicity.

The classification of CNV into genogroups GIV, GVI, and GVII, and their subdivision into genotypes, relies on complete VP1 amino acid sequences, with RdRp sequences used to define P-types. The 2019 update by Chhabra et al. formally recognized two GIV genotypes (GIV.1 and GIV.2), two GVI genotypes (GVI.1 and GVI.2), and one GVII genotype, while also designating a tentative new GVI.3 genotype pending identification of additional related strains [21]. The identification of a novel fox norovirus by Wang et al. (2022), which clustered with canine GVII strains in both VP1 (86.0–86.2% amino acid identity) and RdRp (91.9% amino acid identity), further expands the GVII genogroup and underscores the genetic connectivity of noroviruses circulating among wild and domestic carnivores [9]. These classification schemes are critical for epidemiological surveillance, vaccine development, and risk assessment of zoonotic transmission, and are endorsed by international bodies including the WOAH and the World Health Organization (WHO).

Coinfections and Interspecies Transmission Dynamics

The study of canine norovirus (CNV) has progressively revealed a pathogen that does not operate in isolation. Rather, CNV is embedded within a complex ecological and pathogenic network, characterized by frequent co-detection with other enteric and respiratory pathogens and a growing body of evidence supporting its capacity for interspecies transmission. Understanding these dynamics is critical for accurate diagnosis, disease management, and assessing the true public health and veterinary significance of this emerging virus.

Coinfections: The Multi-Pathogen Enteric Environment

The clinical presentation of acute gastroenteritis in dogs is rarely attributable to a single etiological agent. Extensive epidemiological screening has demonstrated that CNV is frequently found in mixed infections, a phenomenon that complicates the attribution of clinical signs to CNV alone and suggests synergistic or additive pathogenic interactions.

Epidemiological Evidence for Co-Circulation

The advent of multiplex molecular diagnostic platforms has been instrumental in delineating the landscape of coinfections. A recent study from China established a quadruplex RT-qPCR for the simultaneous detection of canine coronavirus (CCoV), canine respiratory coronavirus (CRCoV), canine adenovirus type 2 (CAV-2), and CNV [24]. When applied to 1,688 clinical samples from pet hospitals in Guangxi province (2022–2024), the assay detected CNV at a prevalence of 1.30% (22/1688), alongside CCoV (8.59%), CRCoV (8.65%), and CAV-2 (2.84%) [24]. While this study did not explicitly report the rate of coinfections within individual samples, the co-circulation of these viruses within the same population underscores the potential for frequent mixed infections, particularly exacerbated by the overlap in clinical presentations. The high agreement (>99.53%) between the quadruplex assay and singleplex reference assays further validates the utility of such tools for dissecting these complex multi-pathogen scenarios [24].

Specific Coinfection Partners

Beyond coronaviruses and adenoviruses, CNV has been identified alongside a diverse array of enteric viruses. Data from Southern Italy, analyzing canine samples collected between 2019 and 2021, revealed that CNV (specifically norovirus GIV.2) was detected in dogs co-infected with CCoV, canine parvovirus types 2a/2b/2c, and canine adenovirus type 1 [26]. In this study, 87.2% of CCoV-positive dogs were found to be co-infected with other viral pathogens, highlighting that CNV is a frequent participant in a multi-viral enteric consortium [26].

A broader investigation into the canine fecal virome in Gansu, China, using metatranscriptomic analysis, identified CNV alongside canine astrovirus, canine dicipivirus, canine vesivirus, and canine rotavirus [25]. This analysis confirmed that CNV is part of a complex viral ecosystem within the canine gut, with animal-pathogenic viruses accounting for 19.49% of total viral reads [25]. Further evidence from Shanghai demonstrated CNV co-occurrence with canine kobuvirus. In a study of 60 stray dogs, 25% were positive for canine kobuvirus, and among these, coinfection rates with canine astrovirus reached 73.33%, while coinfection with canine distemper virus, canine coronavirus, and canine rotavirus were 26.67%, 20.00%, and 20.00%, respectively [27]. Notably, CNV was not detected in any of the kobuvirus-positive samples in this particular cohort, suggesting that the ecological niche and transmission dynamics of CNV may differ from those of kobuvirus, or that competitive exclusion may occur under certain conditions [27].

Immunological and Pathological Synergies

The clinical significance of these coinfections is profound. Coinfections with multiple enteric viruses can exacerbate the severity and duration of gastrointestinal disease. The simultaneous infection with CNV and CCoV, for example, could lead to more extensive damage to the intestinal epithelium, compounding fluid loss and malnutrition. The development of diagnostic tools like the quadruplex RT-qPCR is therefore not merely an academic exercise but a direct clinical necessity, as accurate identification of all pathogens involved is paramount for implementing appropriate management strategies, particularly in kennel environments or shelters where outbreaks are common [5, 24]. The gastrointestinal tract is a dynamic interface where the presence of one virus can modulate the host's immune response, potentially altering susceptibility to secondary infections. While direct mechanistic studies of CNV coinfections are limited, the literature from other noroviruses (e.g., murine norovirus) shows that the microbiota and concurrent infections can influence viral tropism and replication kinetics, suggesting similar complex interactions likely occur in the canine host [39, 43].

Interspecies Transmission: A Zoonotic and Cross-Species Concern

Perhaps the most compelling and concerning aspect of CNV biology is its demonstrated or potential for transmission across species boundaries. This is not a theoretical consideration but is supported by a growing body of serological, molecular, and virological evidence.

Evidence for Human-Canine Transmission

The most direct evidence for zoonotic transmission came from a landmark study in Thailand, where recombinant norovirus GII.Pe-GII.4 Sydney, a globally dominant human pandemic strain, was detected in dogs with diarrhea living in a kennel and concurrently in children residing on the same premises [29]. Whole-genome sequencing and phylogenetic analysis confirmed that the canine and human strains were nearly identical, providing the strongest evidence to date of direct human-to-canine transmission of a human norovirus [29]. This event challenges the traditional view of host restriction for norovirus genogroups and suggests that dogs can serve as a spillover host for human GII strains.

Further supporting the possibility of human exposure to canine noroviruses, a serosurvey of 373 small animal veterinarians in Portugal found that 22.3% possessed IgG antibodies against a GVI canine norovirus, compared to only 5.8% of an age-matched population control group (p < 0.001) [13]. This statistically significant difference strongly implies that occupational exposure to dogs increases the risk of encountering CNV, leading to a measurable humoral immune response. A follow-up study across 14 European countries corroborated this, detecting anti-GVI CNV antibodies in dogs and also finding dogs with antibodies against human noroviruses [44]. The presence of antibodies in humans against a virus that is not known to cause clinical disease in them raises critical questions. It could indicate abortive infections, subclinical exposure, or even that CNV is capable of causing mild, undiagnosed gastroenteritis in humans, particularly in those with close canine contact.

Molecular Basis for Cross-Species Binding

The biological plausibility of zoonotic transmission is reinforced by studies on viral attachment factors. Human noroviruses (GI, GII, and GIV) and bovine noroviruses (GIII) bind to specific carbohydrate structures known as histo-blood group antigens (HBGAs). A seminal study by Caddy et al. demonstrated that GIV and GVI CNVs also specifically bind to α1,2-fucose-containing HBGAs (specifically H and A antigens) [31]. This is the same class of carbohydrates used by human GII noroviruses for attachment, a critical first step in infection. Furthermore, the study showed that these HBGAs are expressed in canine saliva and gastrointestinal tissues, and that CNV virus-like particles (VLPs) could bind to these canine tissues [31]. This conservation of receptor binding across genogroups that infect disparate hosts suggests a common ancestral receptor usage and raises the possibility that CNV could theoretically attach to human HBGAs, potentially facilitating infection. The study explicitly concluded that this similarity “raises interesting questions about the evolution of noroviruses and suggests it may be possible for canine norovirus to infect humans” [31].

Feline and Other Carnivore Hosts

The host range of noroviruses classified within GVI and GIV extends beyond canines. GVI strains have been detected in cats, often with a high degree of genetic relatedness to canine strains. A novel feline norovirus identified in Italy was found to be a recombinant virus, with its VP1 capsid closely related to canine GVI.2 strains (81.0–84.0% nt identity) and its polymerase region derived from a different lineage [12]. This suggests that recombination, a major driver of norovirus evolution, can occur across the canine-feline interface. The unrestricted circulation of GVI strains in small carnivores was also reported in a lion, where a norovirus isolate showed 90.1% aa identity in the capsid to the first described canine norovirus [8]. This phylogenetic clustering implies a common ancestor and potential for cross-species jumps within the family Felidae and between felids and canids.

More recently, a novel norovirus was identified in foxes in China, which phylogenetically clustered with canine GVII strains, sharing 86.0-86.2% and 91.9% amino acid identities in VP1 and RdRp, respectively [9]. Interestingly, this fox norovirus was shown to have distinct HBGA binding patterns compared to canine GVII strains, indicating that even within the same genogroup, adaptation to the specific host glycome can occur [9]. These findings collectively illustrate that noroviruses in carnivores are not static entities; they are actively evolving through mutation and recombination, frequently crossing species lines within the order Carnivora.

Implications for Surveillance and Public Health

The cumulative evidence from these studies mandates a paradigm shift in how we view CNV. It is no longer a curiosity of veterinary medicine but a potential player in the ecology of human viral gastroenteritis. The World Health Organization (WHO) has identified norovirus as a priority for vaccine development due to its global burden [19, 22]. The discovery that dogs can harbor and shed human norovirus strains (GII.4) and that humans can seroconvert to CNV, disrupts the conventional understanding of norovirus transmission. It suggests that dogs could act as a reservoir or a mixing vessel, facilitating the emergence of novel recombinant strains with pandemic potential.

Furthermore, the detection of CNV in foxes and its genetic relationship to canine GVII strains expands the potential wildlife reservoir [9]. This has implications for the food and agriculture organization (FAO) and the World Organisation for Animal Health (WOAH), as it underscores the need for a One Health approach to norovirus surveillance. Monitoring CNV evolution and its coinfections in domestic and wild carnivores is not just a veterinary concern; it is a critical component of global public health preparedness. The development of rapid, multiplex diagnostic assays, as pioneered by Shi et al., will be essential for this ongoing surveillance effort, allowing for the early detection of emerging strains and potential interspecies transmission events [24]. The chapter on CNV is, therefore, inextricably linked to the broader narrative of norovirus evolution, zoonotic risk, and the intricate dance between viruses and their hosts across the animal kingdom.

References

[1] Ma H, Yue H, Luo Y, Li S, Tang C. First detection of canine norovirus in dogs and a complete GVI.2 genome in mainland China.. Infection, Genetics and Evolution. 2021. DOI: https://doi.org/10.1016/j.meegid.2021.104879

[2] Bodnar L, Lorusso E, Martino BD, Catella C, Lanave G, Elia G, et al.. Identification of a novel canine norovirus. Infection, Genetics and Evolution. 2017. DOI: https://doi.org/10.1016/j.meegid.2017.04.020

[3] Lyoo K, Jung M, Yoon S, Kim HK, Jeong D. Identification of canine norovirus in dogs in South Korea. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1723-6

[4] Caddy S, Emmott E, El-Attar L, Mitchell J, Rougemont Ad, Brownlie J, et al.. Serological Evidence for Multiple Strains of Canine Norovirus in the UK Dog Population. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0081596

[5] Mesquita J, Nascimento M. Gastroenteritis outbreak associated with faecal shedding of canine norovirus in a Portuguese kennel following introduction of imported dogs from Russia.. Transboundary and Emerging Diseases. 2012. DOI: https://doi.org/10.1111/j.1865-1682.2011.01284.x

[6] Mesquita J, Nascimento M. Molecular epidemiology of canine norovirus in dogs from Portugal, 2007–2011. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-107

[7] Mesquita J, Nascimento M. Serosurvey of veterinary conference participants for evidence of zoonotic exposure to canine norovirus – study protocol. Virology Journal. 2012. DOI: https://doi.org/10.1186/1743-422X-9-250

[8] Martella V, Lorusso E, Decaro N, Elia G, Radogna A, D'abramo M, et al.. Detection and Molecular Characterization of a Canine Norovirus. Emerging Infectious Diseases. 2008. DOI: https://doi.org/10.3201/eid1408.080062

[9] Wang J, Li L, Xu Y, Mao T, Ma Y, Sun X, et al.. fIdentification of a novel norovirus species in fox.. Infection, Genetics and Evolution. 2022. DOI: https://doi.org/10.1016/j.meegid.2022.105214

[10] Alfieri A, Leme RA, Alfieri A. Norovirus Infection. Emerging and Re-emerging Infectious Diseases of Livestock. 2016. DOI: https://doi.org/10.1007/978-3-319-47426-7_6

[11] Soma T, Nakagomi O, Nakagomi T, Mochizuki M. Detection of Norovirus and Sapovirus from diarrheic dogs and cats in Japan. Microbiology and immunology. 2015. DOI: https://doi.org/10.1111/1348-0421.12223

[12] Martino BD, Profio FD, Melegari I, Sarchese V, Cafiero M, Robetto S, et al.. A novel feline norovirus in diarrheic cats. Infection, Genetics and Evolution. 2015. DOI: https://doi.org/10.1016/j.meegid.2015.12.019

[13] Mesquita J, Costantini V, Cannon J, Lin S, Nascimento M, Vinjé J. Presence of Antibodies against Genogroup VI Norovirus in Humans. Virology Journal. 2013. DOI: https://doi.org/10.1186/1743-422X-10-176

[14] Mesquita J, Barclay L, Nascimento M, Vinjé J. Novel Norovirus in Dogs with Diarrhea. Emerging Infectious Diseases. 2010. DOI: https://doi.org/10.3201/eid1606.091861

[15] Mira F, Schiró G, Giudice E, Purpari G, Francesco O, Vicari D, et al.. Viral pathogens in domestic cats in southern Italy: A retrospective analysis in Sicily, 2020-2022.. Comparative Immunology, Microbiology & Infectious Diseases. 2024. DOI: https://doi.org/10.1016/j.cimid.2024.102209

[16] Deus DRD, Siqueira JAM, Maués MAC, Figueiredo MJdFMd, Júnior E, Bandeira RdS, et al.. Analysis of viral diversity in dogs with acute gastroenteritis from Brazilian Amazon.. Infection, Genetics and Evolution. 2024. DOI: https://doi.org/10.1016/j.meegid.2024.105637

[17] Martella V, Pinto P, Buonavoglia C. Canine Noroviruses. The Veterinary clinics of North America. Small animal practice. 2011. DOI: https://doi.org/10.1016/j.cvsm.2011.08.002

[18] Ford-Siltz L, Mullis L, Sanad Y, Tohma K, Lepore C, Azevedo M, et al.. Genomics Analyses of GIV and GVI Noroviruses Reveal the Distinct Clustering of Human and Animal Viruses. Viruses. 2019. DOI: https://doi.org/10.3390/v11030204

[19] Carlson KB, Dilley A, O'grady TB, Johnson JA, Lopman B, Viscidi E. A narrative review of norovirus epidemiology, biology, and challenges to vaccine development. npj Vaccines. 2024. DOI: https://doi.org/10.1038/s41541-024-00884-2

[20] Winder N, Gohar S, Muthana M. Norovirus: An Overview of Virology and Preventative Measures. Viruses. 2022. DOI: https://doi.org/10.3390/v14122811

[21] Chhabra P, Graaf Md, Parra GI, Chan M, Green K, Martella V, et al.. Updated classification of norovirus genogroups and genotypes.. Journal of General Virology. 2019. DOI: https://doi.org/10.1099/jgv.0.001318

[22] Esposito S, Principi N. Norovirus Vaccine: Priorities for Future Research and Development. Frontiers in Immunology. 2020. DOI: https://doi.org/10.3389/fimmu.2020.01383

[23] Parra GI. Emergence of norovirus strains: A tale of two genes.. Virus Evolution. 2019. DOI: https://doi.org/10.1093/ve/vez048

[24] Shi K, Shi Y, Shi Y, Long F, Yin Y, Pan Y, et al.. Establishment of a Quadruplex RT-qPCR for the Detection of Canine Coronavirus, Canine Respiratory Coronavirus, Canine Adenovirus Type 2, and Canine Norovirus. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13121054

[25] Gao W, Yao Y, Sun Y, Pu W, Xu L. Metatranscriptomic characterization of the canine fecal virome from pooled samples in Gansu, China. Virus Research. 2025. DOI: https://doi.org/10.1016/j.virusres.2025.199666

[26] Mira F, Schiró G, Lanave G, Chiaramonte G, Canuti M, Giudice E, et al.. Molecular Screening and Characterization of Canine Coronavirus Types I and II Strains from Domestic Dogs in Southern Italy, 2019–2021. Transboundary and Emerging Diseases. 2024. DOI: https://doi.org/10.1155/2024/7272785

[27] Deng B, Song Y, Li L, Zhou Y, Zhu C, Zhang W, et al.. Detection and genetic characterization of canine kobuvirus from stray dogs in Shanghai, China. Archives of Virology. 2023. DOI: https://doi.org/10.1007/s00705-023-05710-z

[28] Stamelou E, Giantsis IA, Papageorgiou K, Petridou E, Davidson I, Polizopοulou ZS, et al.. First report of canine Astrovirus and Sapovirus in Greece, hosting both asymptomatic and gastroenteritis symptomatic dogs. Virology Journal. 2022. DOI: https://doi.org/10.1186/s12985-022-01787-1

[29] Charoenkul K, Nasamran C, Janetanakit T, Tangwangvivat R, Bunpapong N, Boonyapisitsopa S, et al.. Human Norovirus Infection in Dogs, Thailand. Emerging Infectious Diseases. 2020. DOI: https://doi.org/10.3201/eid2602.191151

[30] Caddy S, Rougemont Ad, Emmott E, El-Attar L, Mitchell J, Hollinshead M, et al.. Evidence for Human Norovirus Infection of Dogs in the United Kingdom. Journal of Clinical Microbiology. 2015. DOI: https://doi.org/10.1128/JCM.02778-14

[31] Caddy S, Breiman A, Pendu JL, Goodfellow I. Genogroup IV and VI Canine Noroviruses Interact with Histo-Blood Group Antigens. Journal of Virology. 2014. DOI: https://doi.org/10.1128/JVI.01008-14

[32] Darold GM, Benetti-Gomes AH, Amude AM, Vieira RR, Filho LFCdC, Lunardi M. Investigação Molecular da Infecção Pelo Norovírus em Filhotes de Cães Domésticos de Cuiabá, Mato Grosso. Ensaios e Ciência C Biológicas Agrárias e da Saúde. 2024. DOI: https://doi.org/10.17921/1415-6938.2024v28n1p39-43

[33] Kendra J, Tohma K, Parra GI. Global and regional circulation trends of norovirus genotypes and recombinants, 1995–2019: A comprehensive review of sequences from public databases. Reviews in Medical Virology. 2022. DOI: https://doi.org/10.1002/rmv.2354

[34] Matamoros D, Worsfold C, Campos RC, Acuña HMB, Chacón EC, Sánchez C. Molecular characterization of norovirus and sapovirus detected in animals and humans in Costa Rica: Zoo-anthropozoonotic potential of human norovirus GII.4. Open Veterinary Journal. 2023. DOI: https://doi.org/10.5455/OVJ.2023.v13.i1.8

[35] Murakami K, Murakami K, Tenge VR, Karandikar UC, Lin S, Ramani S, et al.. Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. Proceedings of the National Academy of Sciences of the United States of America. 2020. DOI: https://doi.org/10.1073/pnas.1910138117

[36] Jin M, Wu S, Kong X, Xie H, Fu J, He Y, et al.. Norovirus Outbreak Surveillance, China, 2016–2018. Emerging Infectious Diseases. 2020. DOI: https://doi.org/10.3201/eid2603.191183

[37] Green K, Kaufman S, Nagata BM, Chaimongkol N, Kim DY, Levenson EA, et al.. Human norovirus targets enteroendocrine epithelial cells in the small intestine. Nature Communications. 2020. DOI: https://doi.org/10.1038/s41467-020-16491-3

[38] Nordgren J, Svensson L. Genetic Susceptibility to Human Norovirus Infection: An Update. Viruses. 2019. DOI: https://doi.org/10.3390/v11030226

[39] Grau KR, Zhu S, Peterson ST, Helm EW, Philip DT, Phillips M, et al.. Commensal bacteria regulate regionalization of acute norovirus infection along the intestinal tract through bile acid-mediated priming of type III interferon. Nature Microbiology. 2019. DOI: https://doi.org/10.1038/s41564-019-0602-7

[40] Hosmillo M, Chaudhry Y, Nayak KM, Sorgeloos F, Koo B, Merenda A, et al.. Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses. mBio. 2019. DOI: https://doi.org/10.1128/mBio.00215-20

[41] Chhabra P, Browne H, Huynh T, Diez-Valcarce M, Barclay L, Kosek M, et al.. Single-step RT-PCR assay for dual genotyping of GI and GII norovirus strains. Journal of Clinical Virology. 2020. DOI: https://doi.org/10.1016/j.jcv.2020.104689

[42] Brocard M, Iadevaia V, Klein P, Hall B, Lewis G, Lu J, et al.. Norovirus infection results in eIF2α independent host translation shut-off and remodels the G3BP1 interactome evading stress granule formation. PLoS Pathogens. 2020. DOI: https://doi.org/10.1371/journal.ppat.1008250

[43] Wilen CB, Lee S, Hsieh LL, Orchard R, Desai C, Hykes BL, et al.. Tropism for tuft cells determines immune promotion of norovirus pathogenesis. Science. 2018. DOI: https://doi.org/10.1126/science.aar3799

[44] Mesquita J, Delgado ILS, Costantini V, Heenemann K, Vahlenkamp T, Vinjé J, et al.. Seroprevalence of Canine Norovirus in 14 European Countries. Clinical and Vaccine Immunology. 2014. DOI: https://doi.org/10.1128/CVI.00048-14

[45] Shaffer M, Huynh K, Costantini V, Bibby K, Vinjé J. Viable Norovirus Persistence in Water Microcosms.. Environmental Science and Technology Letters. 2022. DOI: https://doi.org/10.1021/acs.estlett.2c00553

[46] Lucero Y, Matson D, Ashkenazi S, George S, O'ryan M. Norovirus: Facts and Reflections from Past, Present, and Future. Viruses. 2021. DOI: https://doi.org/10.3390/v13122399

[47] Calderwood LE, Wikswo M, Mattison CP, Kambhampati AK, Balachandran N, Vinjé J, et al.. Norovirus Outbreaks in Long-term Care Facilities in the United States, 2009–2018: A Decade of Surveillance. Clinical Infectious Diseases. 2021. DOI: https://doi.org/10.1093/cid/ciab808

[48] Weerathunge P, Ramanathan R, Torok V, Hodgson KR, Xu Y, Goodacre R, et al.. Ultrasensitive Colorimetric Detection of Murine Norovirus Using NanoZyme Aptasensor.. Analytical Chemistry. 2019. DOI: https://doi.org/10.1021/acs.analchem.8b03300

[49] Estes M, Ettayebi K, Tenge VR, Murakami K, Murakami K, Karandikar UC, et al.. Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. Viruses. 2019. DOI: https://doi.org/10.3390/v11070638

[50] Burke R, Mattison CP, Pindyck T, Dahl R, Rudd J, Bi D, et al.. The Burden of Norovirus in the United States, as Estimated Based on Administrative Data. Clinical Infectious Diseases. 2020. DOI: https://doi.org/10.1093/cid/ciaa438

[51] Bartsch S, O'Shea KJ, Lee BY. The Clinical and Economic Burden of Norovirus Gastroenteritis in the United States.. Journal of Infectious Diseases. 2020. DOI: https://doi.org/10.1093/infdis/jiaa292

[52] Costantini V, Morantz EK, Browne H, Ettayebi K, Zeng X, Atmar R, et al.. Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. Emerging Infectious Diseases. 2018. DOI: https://doi.org/10.3201/eid2408.180126